Answers are grounded in this paper and cite their sources.
Artemisinin Combination Therapy (ACT) is readily available in malaria-endemic nations, leading to repeated drug usage by undiagnosed persons. Repeated use of ACT therapy by non-infected individuals may affect blood cells. This study explored how repeated artesunate-amodiaquine (A/A) and artemether-lumefantrine (A/L) treatment in non-infected mice affected haematological markers. 100 male BALB/c mice were randomly divided into 5 groups: non-infected and Plasmodium berghei NK65 infected treated with A/L and A/A 1X, 2X, 3X, 4X, 5X, and 6X, and the control group. Packed cell volume (PCV), Haemoglobin (Hb), and red blood cell (RBC) were reduced (p>0.05) non-significantly in the non-infected group treated with A/L or A/A six times compared to the control and infected groups. WBC rose in infected and non-infected mice treated with A/L or A/A 1X, 2X, 3X, and 6X, with a substantial rise in non-infected mice treated with A/L (p < 0.01) and A/A (p < 0.001) three times. WBC mainly rose due to lymphocytes, although neutrophils decreased. Repeated therapeutic use of A/L and A/A without infection may cause a haematological change. Continuous efforts are needed to educate the public about screening for malaria parasites before using drugs.
No takes yet. Share an insight, caveat, or question.
Audu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: